Adjunct Therapy with Ipragliflozin Exerts Limited Effects on Kidney Protection in Type 1 Diabetes: A Retrospective Study Conducted at 25 Centers in Japan (IPRA-CKD)
Authors:
- Yuta NakamuraYNYuta Nakamura
- Ichiro HorieIHIchiro Horie
- Hiroshi YanoHYHiroshi Yano
- Hiroshi NomotoHNHiroshi Nomoto
- Tomoyasu FukuiTFTomoyasu Fukui
- Yoshihiko YuyamaYYYoshihiko Yuyama
- Tomoyuki KawamuraTKTomoyuki Kawamura
- Mariko UedaMUMariko Ueda
- Akane YamamotoAYAkane Yamamoto
- Yushi HirotaYHYushi Hirota
- Yoshiki KusunokiYKYoshiki Kusunoki
- Kenro NishidaKNKenro Nishida
Open Access
- 23 May 2025
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 13 (6) , 1287
Abstract
Background/Objectives: While sodium–glucose cotransporter 2 (SGLT2) inhibitors have demonstrated additional non-glycemic benefits for renal protection in individuals with type 2 diabetes, less evidence is available for those with type 1 diabetes (T1D). To determine whether the adjunctive use of the SGLT2 inhibitor ipragliflozin confers kidney protection in individuals with T1D, we retrospectively analyzed data from a real-world cohort examined at 25 centers in Japan. Methods: We enrolled 359 subjects aged 20–74 years with T1D (IPRA group: 159 ipragliflozin users; control [CTRL] group: 200 non-users). The primary outcome was changes in the estimated glomerular filtration rate (eGFR) from baseline to 24 months after the initiation of ipragliflozin. The secondary outcomes were all other changes, including the urinary albumin–creatinine ratio (UACR) and urinary protein–creatinine ratio (UPCR). Results: The IPRA group’s eGFR decline slopes were 0.79 mL/min/1.73 m2/year milder than the CTRL group’s after propensity score matching, but this difference was not significant. The subjects complicated by chronic kidney disease (CKD) defined as UACR ≥ 30 mg/g and/or UPCR ≥ 0.5 g/g and/or eGFR < 60 mL/min/1.73 m2 showed changes in UPCR (g/g) from baseline to 24 months that were significantly lower in the IPRA group (−0.27 ± 1.63) versus the CTRL group (0.18 ± 0.36) (p = 0.016). No significant increase in adverse events (including severe hypoglycemia and hospitalization due to ketosis/ketoacidosis or cardiovascular diseases) was observed in the IPRA group. Conclusions: Adjunctive treatment with ipragliflozin exerted potential renal benefits by decreasing proteinuria in T1D subjects with CKD. Further investigations are required to determine whether its additional benefits exceed the increased risk of ketoacidosis.Keywords
Funding Information
- Astellas Pharma Inc. (Tokyo, Japan)
This publication has 38 references indexed in Scilit:
- The Effect of Sodium–Glucose Cotransporter Inhibitors on Renal Function as Adjunctive to Insulin in Adults with Type 1 Diabetes: An Updated Multilevel Meta-analysis of Randomized Controlled TrialsDiabetes Therapy, 2024
- Sodium glucose cotransporter2 inhibitors for type 1 diabetes mellitus: A meta-analysis of randomized controlled trialsPrimary Care Diabetes, 2023
- Effects of dapagliflozin on renal function in type 1 diabetes patients in the real world: A retrospective multicenter study of the KAMOGAWA-A cohortDiabetes Research and Clinical Practice, 2023
- Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia, 2022
- Sodium–glucose cotransporter 2 inhibitors as adjunct therapy for type 1 diabetes and the benefit on cardiovascular and renal disease evaluated by Steno risk enginesJournal of Diabetes and its Complications, 2022
- Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trialDiabetologia, 2022
- Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trialsThe Lancet Diabetes & Endocrinology, 2020
- SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 InhibitionCell Metabolism, 2020
- SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risksThe Lancet Diabetes & Endocrinology, 2019
- Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trialThe Lancet Diabetes & Endocrinology, 2017